Subject: Facet Joint Diagnostic Injections for Chronic Spinal Pain

Original Effective Date: 7/5/07

Policy Number: MCR-030

Revision Date(s):
12/08, 6/10, 6/13, 12/13, 6/12/14, 6/15/2016, 7/25/17
This MCR is no longer scheduled for revisions.

Review Date: 6/15/16, 3/8/18, 6/19/19

MCPC Approval Date: 7/25/17, 3/8/18, 6/19/19

DISCLAIMER

This Molina Clinical Review (MCR) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this Molina Clinical Review (MCR) document and provide the directive for all Medicare members.

DESCRIPTION OF PROCEDURE/SERVICE/PHARMACEUTICAL

Facet joint syndrome is a condition that leads to chronic spinal pain due to unclear etiology. The classic findings of facet joint syndrome are pain in the cervical or thoracic spine or low back radiating to the buttock and posterior thigh, pain due to hyperextension, pain on palpation of joint, and absence of both radiculopathy below the knee and neurologic deficits.

Facet blocks can be performed in cervical, thoracic, or lumbar segments of the spine and may be performed as a diagnostic or therapeutic procedure. Facet blocks using short or long-acting local anesthetics can be used to diagnose facet (zygapophyseal) joint syndrome as the cause of chronic back pain. Diagnostic injections involve the injection of a local anesthetic into the facet joints (intra-articular) or around the nerve supply to the joints (medial branches of the dorsal rami aka medial branch block). Injections should be fluoroscopically guided. Pain relieved following the injection for the appropriate amount of time given the type of medication used, without definitive clinical or imaging findings, would suggest that the pain originated in the facet joint. A positive diagnostic block is the prerequisite for undergoing other treatments to alleviate facet joint pain such as *radiofrequency denervation of the facet joints.

INITIAL COVERAGE CRITERIA

1. Diagnostic facet joint injections may be considered medically necessary for facet joint pain in adults who are age 18 years or older as part of a comprehensive pain management treatment program when all of the following criteria are met: [ALL]
   ☐ Presence of chronic severe back pain (cervical, or lumbar) that is predominantly axial not associated with radiculopathy or neurogenic claudication present for a minimum of 3 months that is: [ALL]
     ○ resulting from disease, injury or surgery; and
confirmed by provocative testing resulting in reproducible pain (i.e., hyperextension, rotation); and

Pain is affecting activity of daily living functional ability: > 4 on the NRS Pain Rating Scale*; and

Physical evaluation has ruled out that no non-facet pathology that could explain the source of the patient’s pain, such as discogenic, sacroiliac joint pain, disc herniation, fracture, tumor, infection; and

AND

Has tried and failed conservative therapy (i.e. for the current episode of pain (within the last 3 months) that includes: [ALL]

- Physical therapy (PT) a minimum of 10-12 sessions over 8 weeks; or
- There must be documentation submitted that explains why physical therapy is contraindicated:
  *Note: PT may be contraindicated if any of the following are present:
  ➢ pain worsened with PT;
  ➢ PT tried but was not able to be tolerated
  AND
- Activity modification a minimum of 6 weeks; and
- Drug therapy (i.e. NSAIDS, muscle relaxants, corticosteroids, antidepressants, anticonvulsants, or opiates)

*The Numeric Rating Scale (NRS-11): Rating Pain Level

- 0: No Pain
- 1 – 3: Mild Pain (nagging, annoying, interfering little with ADLs)
- 4 – 6: Moderate Pain (interferes significantly with ADLs)
- 7 – 10: Severe Pain (disabling; unable to perform ADLs)

2. Initial Diagnostic Injection and Frequency Criteria:

- For each spinal region (cervical-or lumbar) injections/blocks performed will be limited to a maximum of 2 levels (3 nerves) injected on the same date of service (session/procedure):
  - The same level or levels bilaterally may be injected during the same session/procedure (6 nerves total for 2 levels bilaterally)
- A diagnostic block can be repeated once, at any given level, at least one week (preferably 2 weeks) after the first block. If repeated, strong consideration should be given to utilizing administration of an anesthetic of different duration of action. (This helps confirm the validity of the diagnostic facet block, and may reduce the incidence of false positive responses due to placebo effect); and
- Maximum of 3 procedures (sessions) per region every 6 months

3. Repeat Diagnostic Facet Injection Criteria:

- Documented positive response to diagnostic block(s) in a different level as evidenced by 50% symptom or significant functional pain relief (using visual analog scale or verbal descriptor scale) within 1 hour using short acting local anesthetic or 2 hours with longer-acting anesthetic achieved for both blocks
- When there is significant functional pain relief of 50% measured by a decrease in pain medications and increase in physical function from a single diagnostic facet joint injection/medial branch block, there is sufficient evidence of facet pathology, a second confirmatory block is NOT medically necessary.
- Once a diagnostic paravertebral block is negative at a specific level, no repeat interventions should be directed at that level unless there is a new clinical presentation with symptoms, signs, and diagnostic studies of known reliability and validity that implicate that level (new review of criteria would be indicated)
Definitions:

- A zygapophyseal (facet) joint level is defined as the zygapophyseal joint or the two medial branch (MB) nerves that innervate that zygapophyseal joint.
- A session is defined as all injections/blocks procedures performed on one day and includes medial branch blocks (MBB), and intraarticular injections (IA).
- A region is defined as all injections performed in cervical/thoracic or all injections performed in lumbar (not sacral) spinal areas.

*Please refer to Radiofrequency Ablation MCR-085 for additional criteria*

Note: Criteria recommendations are mainly obtained from CMS,¹ and the Official Disability Guidelines (2017). ⁵⁴⁻⁵⁵

### Coverage Exclusions ⁵³⁻⁵⁴⁻⁵⁶

- **Therapeutic** or subsequent facet injections/medial branch blocks at the same level are considered experimental, investigational or unproven as there is insufficient data to support the effectiveness of these interventions.
- Facet joint injections in the thoracic region are considered experimental, investigational and unproven.
- The performance of facet joint injections/medial branch blocks in the presence of an untreated radiculopathy is considered not medically necessary.
- The performance of injections/blocks on more than two (2) levels one the same day is considered not medically necessary.
- The following are considered contraindications to the procedure and require physician documentation of medical necessity in the presence of any the following:
  - previous history of spinal fusion in the area treated
  - unstable medical conditions or psychiatric illness
  - current anticoagulation treatment
  - current systemic infection or infection over the injection site

### Summary of Medical Evidence ³⁻⁴¹

There is a moderate amount of clinical reports and reviews of facet blocks for chronic back pain published in the peer reviewed medical literature consisting of systematic reviews, randomized controlled trials or controlled trials with ≥ 40 patients and uncontrolled trials with ≥ 100 patients. ³⁻³⁷ Studies primarily addressed the diagnosis and/or treatment of patients with chronic low (lumbar) back pain and involved patients with cervical or thoracolumbar pain. Outcome measures varied among studies but generally included assessment of pain, assessment of ability to perform functions of daily living and to return to previous work, use of pain medication, and patient satisfaction. The randomized controlled trials reported a relatively large placebo effect, with improvement in all groups, but no difference in clinical response between local anesthetic block and placebo (saline injection). One study reported some improvement in lumbar mobility but no greater improvement in pain or disability when facet injections were added to an exercise program compared with exercise alone. The uncontrolled studies reported conflicting results regarding the accuracy of facet blocks for identifying facet joint syndrome as a cause of chronic back pain, but all reported relief of pain in some patients following facet block. The Cochrane systematic review analyzed 21 randomized trials and found that there was no convincing evidence for the therapeutic efficacy of facet joint blocks in patients with lower back pain. The primary outcome measure was pain relief, and all of the studies that involved patients with low back pain persisting longer than 1 month were reviewed. The overall body of evidence regarding facet injections as a treatment for chronic neck and back pain shows that while facet blocks...
are associated with some pain relief; most studies suggest that the effects are attributable to the anesthetic or placebo effect. 38-39

The 2015 AHRQ comparative effectiveness study on injection therapies for low back pain concluded that the studies found no clear differences between various facet joint corticosteroid injections (intraarticular, extra-articular [peri-capsular], or medial branch) and placebo interventions. 40

*Professional Society Guidelines* indicate that diagnostic cervical facet joint nerve blocks are recommended in patients with somatic or non-radicular neck pain or headache and upper extremity pain, with duration of pain of at least 3 months, without preponderance of evidence of discogenic pain, disc herniation, or evidence of radiculitis. Diagnostic lumbar facet joint nerve blocks are recommended in patients with suspected facet joint pain. 43

**Coding Information:** The codes listed in this policy are for reference purposes only. Listing of a service or device code in this policy does not imply that the service described by this code is a covered or non-covered. Coverage is determined by the benefit document. This list of codes may not be all inclusive.

<table>
<thead>
<tr>
<th>CPT</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64490</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; single level</td>
</tr>
<tr>
<td>64491</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64492</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64493</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; single level</td>
</tr>
<tr>
<td>64494</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>64495</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with image guidance (fluoroscopy or CT), lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0213T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level</td>
</tr>
<tr>
<td>0214T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0215T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0216T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level</td>
</tr>
<tr>
<td>0217T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>0218T</td>
<td>Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>
**RESOURCE REFERENCES**

**Government Agency**

**Peer Reviewed Publications**


Professional Society Guidelines


43. American Society of Interventional Pain Physicians (ASIPP):


48. American Pain Society:

Other Resources
   ● Intra-articular Facet Joint Injections for the Treatment of Chronic Nonmalignant Spinal Pain of Facet Joint Origin. April, 2018

   ● Chou R. Subacute and chronic low back pain: Nonsurgical interventional treatment. Literature review current through.
   ● Zacharia I. Treatment of Neck Pain. Literature review current through.

   ● Facet joint diagnostic blocks (injections).
   ● Facet joint injections, lumbar
- Facet joint injections, multiple series
- Facet joint injections, thoracic
- Facet joint intra-articular injections (therapeutic blocks)
- Facet joint medial branch blocks (therapeutic injections)

- Facet joint diagnostic blocks


Revision History:
7/17: Reduced PT requirement from 20 sessions to 10-12 sessions over 8 weeks, changed improvement scales from significant functional improvement of 80% to significant functional pain relief of 50% measured by a decrease in pain medication and increase in functional ability, changed diagnostic injection criteria from 3 levels to 2 levels, removed significant narrowing of the vertebral canal or spinal instability as a contraindication, added that thoracic region injections are considered experimental, investigational and unproven and removed the requirement for a comprehensive psychosocial assessment. Changes are based on 2017 ODG Guidelines per AMR review.
3/8/18 & 6/19/19: Policy reviewed, no changes to criteria.